US Earnings Financial Results SEC Filings — July 14, 2026
This digest of 36 filings reveals a market bifurcated between a handful of growth stories and a broad swath of micro-cap companies in severe financial distress. Revenue growth is highly concentrated, with only a few companies like Kestra Medical Technologies (+59% YoY) and AngioDynamics (+9.5% YoY) showing robust top-line expansion, while many others, including Americas CarMart (-10.3% YoY) and SemiLEDs (-57.3% YoY), experienced sharp revenue declines. A dominant theme is the widening of net losses across the portfolio, with 13 out of 36 companies reporting a deterioration in profitability, often driven by surging operating expenses, interest costs, or non-cash charges like impairments and derivative losses. Capital allocation is overwhelmingly focused on survival, with numerous companies relying on related-party debt, dilutive equity issuances, or convertible notes to fund operations, and insider activity is notably absent from the filings, suggesting a lack of management conviction. The most critical development is the high number of going-concern warnings and default situations, particularly in the energy and technology sectors, which poses significant risk for investors. The market implications are clear: a flight to quality is warranted, favoring companies with positive operating cash flow and sustainable growth, while avoiding the deep-value traps in the micro-cap space.